| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 27.66% | Piper Sandler | $3.5 → $3 | Maintains | Neutral |
| 09/21/2023 | 197.87% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/31/2023 | 155.32% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 08/24/2023 | 155.32% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 580.85% | Benchmark | → $16 | Reiterates | Buy → Buy |
| 06/22/2023 | 155.32% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 580.85% | Benchmark | → $16 | Reiterates | Buy → Buy |
| 03/27/2023 | 580.85% | Benchmark | → $16 | Reiterates | → Buy |
| 07/18/2022 | 325.53% | BTIG | $12 → $10 | Maintains | Buy |
| 10/29/2021 | 623.4% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 09/24/2021 | 580.85% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 708.51% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 09/16/2021 | 623.4% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
What is the target price for Humacyte (HUMA)?
The latest price target for Humacyte (NASDAQ: HUMA) was reported by Piper Sandler on November 10, 2023. The analyst firm set a price target for $3.00 expecting HUMA to rise to within 12 months (a possible 27.66% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Humacyte (HUMA)?
The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Piper Sandler, and Humacyte maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
Is the Analyst Rating Humacyte (HUMA) correct?
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a maintained with a price target of $3.50 to $3.00. The current price Humacyte (HUMA) is trading at is $2.35, which is out of the analyst's predicted range.